Thymosin Beta-4 (TB-500) is a peptide known for its ability to promote regeneration in the body. Studies in animals have demonstrated that the use of Thymosin Beta-4 can help to heal wounds in dermal, corneal, and cardiac cells, improve cell survival, promote blood vessel formation, and increase the maturation of stem cells. Thymosin Beta-4 has also been found to decrease levels of inflammatory cytokines and chemokines.
Research conducted on rats and mice demonstrated the efficacy of topical Thymosin Beta-4 in treating alkali and heptanol-related injuries to the eyes and skin. By administering 5 micrograms/5 microliters of Thymosin Beta-4 liquid eye drops twice per day, the corneal epithelium moved rapidly over the surface of the cornea to repair alkali injury. Thymosin Beta-4 alleviates inflammation by decreasing the levels of matrix metalloproteinases, activating nF kappa b, and blocking TNF cytokine release. Thymosin Beta-4 also increases the synthesis of laminin-5, which promotes cell contact and migration in the corneal epithelium and decreases apoptosis while increasing the rate of angiogenesis.
In another study, Thymosin Beta-4 was used to treat dermal wounds in rats and mice. Animals were treated with either a PBS form or a hydrogel of Thymosin Beta-4 in doses varying from 5 to 50 micrograms/50 microliters/wound. The application of Thymosin Beta-4 led to an increase in the rate of collagen deposition, keratinocyte migration, and angiogenesis. Studies conducted on rats and mice with various forms of impaired healing such as diabetes or advanced age reported that the use of Thymosin Beta-4 accelerated the healing process in the test subjects.
Thymosin Beta-4 has been shown to have positive effects in various animals when treating cardiovascular disease, nerve damage, septic shock, and dermal injury. For intracardiac injection of Thymosin Beta-4, the typical dose was 400 ng, while retro infusion doses ranged around 15 mg. In the coronary ligation models in mice, Thymosin Beta-4 promoted repair throughout the cardiac muscle. Additionally, in the refusion injury model of sheep, Thymosin Beta-4 prevented damage to the vascular system.
Thymosin Beta-4 helps to lower inflammation in the body and reduce levels of proinflammatory cytokines. In a study conducted by Phlip and Kleinman, endotoxins were injected into rats to examine the anti-inflammatory properties of Thymosin Beta-4. After dosing with Thymosin Beta-4, the lethality of endotoxin-induced septic shock was greatly reduced, as well as the inflammatory mediators found in association with septic shock. Reduced levels of Thymosin Beta-4 were found in rats with non-induced septic shock as well as when injected with the endotoxin, indicating that Thymosin Beta-4 can play an important role in treating sepsis.
According to this study, the administration of Thymosin Beta-4 resulted in a significant reduction in the lethality of endotoxin-induced septic shock and the associated inflammatory mediators. Interestingly, the levels of Thymosin Beta-4 were found to decrease naturally when sepsis was induced in rats. Lower levels of Thymosin Beta-4 were also observed in rats with non-induced septic shock or those injected with endotoxin, suggesting that Thymosin Beta-4 may play a crucial role in sepsis treatment.
Similar to its protective role in the cardiovascular system, Thymosin Beta-4 has demonstrated a protective effect on the nervous system both in vivo and in vitro. In rats, Thymosin Beta-4 was found to combat the loss of hippocampal neurons induced by kainic acid treatment when administered twice daily for 5 days.
In another study, treatment with Thymosin Beta-4 was shown to improve functionality, increase the amount of mature oligodendrocytes, and reduce inflammation in mice with autoimmune encephalomyelitis. Thymosin Beta-4 was also found to protect against glutamate-induced and ethanol toxicity in vitro.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
TB-500 Capsules are an oral research-format option designed for laboratories and research teams evaluating thymosin beta-related pathways, cytoskeletal dynamics, and tissue integrity signaling in controlled study environments. TB-500 is commonly discussed as a thymosin beta-4-derived research fragment used in preclinical models that explore actin regulation, cell migration, angiogenic signaling, and recovery-adjacent endpoints. This capsule-based format is positioned for research teams that prefer non-injectable handling and standardized unit consistency for protocol documentation.
Because recovery-oriented study designs often involve multiple interacting pathways, TB-500 capsule protocols are frequently discussed alongside research compounds tied to tissue integrity and systemic context, including BPC 157, BPC 157 Capsules, and Thymalin. These comparative structures help researchers distinguish cytoskeletal and migration-focused signaling from immune and barrier-related variables within the same broader recovery framework.
TB-500 Capsule Research Specifications:
| Format | Capsules |
| Unit Quantity | See product listing for capsule count and total content per unit |
| Purity / Testing | Research-grade raw material supported by lot-level analytical verification where applicable |
| Compound Context | TB-500 is widely referenced as a thymosin beta-4-related research peptide used in tissue integrity, recovery, and cellular migration pathway studies |
| Appearance | Encapsulated powder |
| Storage Conditions | Store in a cool, dry environment away from direct light and moisture. For best practices in peptide handling and stability controls, reference internal laboratory SOPs and storage documentation. |
| Research Use Only | This product is supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
In the peptide research landscape, TB-500 is routinely linked to thymosin beta activity and actin-binding dynamics. Actin regulation is a foundational cellular control layer for migration, wound-model behavior, and tissue remodeling readouts. Because of that, TB-500 often appears in study designs that track cellular movement, extracellular matrix context, and angiogenic signaling markers over time.
For teams building broader recovery-oriented models, TB-500 is frequently discussed alongside gut and connective-tissue integrity variables such as BPC 157. In comparative designs, TB-500 can be positioned as a cell-migration and cytoskeletal-dynamics input, while BPC 157 is framed more as a tissue-integrity and repair-signaling input. When researchers want to pair immunomodulatory context, compounds like Thymalin may be included to evaluate whether immune-signaling shifts correlate with recovery-adjacent endpoints.
Capsule format adds another layer to experimental design. Researchers can use this presentation to study oral-format standardization, capsule consistency, GI passage assumptions, and route-specific protocol differences relative to vialed peptide workflows. That makes TB-500 Capsules relevant not just for pathway analysis, but also for formulation and delivery-format comparisons in tightly controlled preclinical environments.
Important Research Notice: Nordsci peptides are supported by third-party analytical testing to validate identity and purity where applicable. A Certificate of Analysis is available for qualifying lots to support documentation, traceability, and internal quality controls.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
TB-500 is commonly included in research discussions focused on actin regulation and downstream cellular movement. In practical terms, this can translate into assay frameworks that observe migration rates, wound-model closure dynamics, or tissue remodeling behavior in controlled environments. These designs typically emphasize time-series sampling and standardized exposure windows to reduce interpretive noise.
In recovery-oriented preclinical models, TB-500 is frequently connected to tissue remodeling and angiogenic signaling themes. Researchers may incorporate vascularization markers, extracellular matrix remodeling readouts, and histology-driven outcomes to determine whether pathway signals change in parallel with functional measures.
Because TB-500 and BPC 157 are commonly discussed together in recovery-focused research communities, a frequent experimental approach is comparative arm design. This structure helps teams isolate whether outcomes appear more aligned with cytoskeletal dynamics and migration signaling versus tissue integrity and repair signaling, while controlling for handling and environmental variables. Capsule-versus-vial comparisons can add further clarity when route and format are part of the study question.
In protocols where immune signaling is treated as a confounder for recovery outcomes, researchers may include immunomodulatory peptides such as Thymalin to map whether immune markers correlate with tissue remodeling readouts. This can be useful when the goal is to separate local tissue effects from broader systemic context within a complex repair model.
COA documentation, where applicable, supports traceability and quality-managed research operations. For qualifying lots, COA materials document identity and analytical verification and can be used for internal audits, protocol files, and procurement recordkeeping.
When sourcing capsule-format peptide products, prioritize clear labeling, unit consistency, and documentation that supports traceability. Labs operating with strict SOPs should maintain controlled storage practices and standardized intake documentation to reduce avoidable variability across cohorts.
IMPORTANT: TB-500 Capsules are sold exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. Researchers are responsible for compliance with all applicable regulations and institutional policies governing peptide research in their jurisdiction.
